Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The Contour Neurovascular System (CNS, Stryker, Kalamazoo, MI) has a unique design that allows it to address various aneurysm morphologies, including wide-necked, irregular, and shallow-shaped lesions. However, evidence of its safety and efficacy remains limited. This systematic review and meta-analysis synthesizes the current data on CNS performance.

Methods: A comprehensive search guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) standards was performed across PubMed, Embase, and Web of Science, including studies with ≥5 patients reporting on CNS use. Efficacy outcomes included immediate and last follow-up adequate aneurysm occlusion and technical success. Safety outcomes included good functional outcome (modified Rankin Scale (mRS) score of 0-2 at last follow-up), procedure-related morbidity (permanent neurological deficits), procedure-related mortality, intraoperative and postoperative complications. Pooled analyses with 95% confidence intervals (CI) were conducted, with heterogeneity assessed using I² statistics, and a random-effects model was applied.

Results: Nine studies, including 483 patients (58.8% female; mean age: 59.3±15.6 years) with 484 aneurysms, were analyzed. Of the 467 patients in whom rupture status was reported, 81.8% presented with unruptured aneurysms and 18.2% with ruptured aneurysms. Immediate adequate aneurysm occlusion rate was 53% (95% CI: 1% to 100%), with follow-up adequate occlusion at 93% (95% CI: 88% to 97%) and technical success at 98% (95% CI: 95% to 100%). Intraoperative and postoperative complication rates were 3% (95% CI: 0% to 7%) and 7% (95% CI: 3% to 12%), respectively. Procedure-related morbidity was 2% (95% CI: 0% to 3%), with no procedure-related mortality.

Conclusion: The CNS is a safe and effective novel intrasaccular device for treating intracranial aneurysms.

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnis-2024-022461DOI Listing

Publication Analysis

Top Keywords

safety efficacy
8
contour neurovascular
8
neurovascular system
8
treating intracranial
8
intracranial aneurysms
8
systematic review
8
review meta-analysis
8
outcomes included
8
follow-up adequate
8
adequate aneurysm
8

Similar Publications

Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events.

Nano Lett

September 2025

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, China.

Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety.

View Article and Find Full Text PDF

BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.

View Article and Find Full Text PDF

IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.

View Article and Find Full Text PDF

Oral immunotherapy in children with allergic diseases: past, present and future.

Minerva Pediatr (Torino)

September 2025

Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.

Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limited settings. Moreover, the healthcare sector is a significant source of greenhouse gas emissions, and medication-related waste-such as that from vial-based therapies-has been identified as a contributing factor. Alternative dosing strategies could reduce the environmental and financial impact of ICI therapy while maintaining clinical safety and efficacy.

View Article and Find Full Text PDF